Pharminent

FDA expands Pfizer’s Talzenna-Xtandi label to hormone-sensitive prostate cancer

The FDA expanded the label for Pfizer’s Talzenna in combination with Xtandi to hormone-sensitive prostate cancer, moving the combination to an earlier line of therapy.

Bayer’s asundexian approved in China for secondary stroke prevention

Bayer’s oral Factor XIa inhibitor asundexian has been cleared in China for secondary stroke prevention, its first market approval.

AstraZeneca’s claudin ADC cuts risk of death 53% in GI cancers

AstraZeneca’s CLARITY-Gastric01 trial of sone-ve in CLDN18.2-positive gastrointestinal cancers showed a 53% reduction in the risk of death, doubling survival.

Roche reports positive lung cancer data for KRAS drug divarasib

Roche presented data at ESMO from a study of its KRAS inhibitor divarasib in lung cancer, described as one of the meeting’s more impressive data sets.

Bristol Myers Squibb discloses patient death in CAR-T multiple sclerosis trial

Bristol Myers Squibb disclosed a patient death in a clinical trial of its CAR-T cell therapy in multiple sclerosis.

BioNTech and DualityBio report modest ADC benefit in HER2-low breast cancer

BioNTech and DualityBio said their antibody-drug conjugate produced a “modest” benefit in a breast cancer study, with the companies describing the treatment’s impact in HER2-low breast cancer as “limited.”

Orpathys Phase III SANOVO data support first-line use in NSCLC subgroup

Positive Phase III results from the SANOVO and SAFFRON studies backed first-line use of Orpathys in a non-small cell lung cancer subgroup, though adverse events tempered the reaction.

GSK’s ris-rez shows benefit in osteosarcoma study at ESMO

A new study presented at ESMO suggests GSK’s ris-rez could improve treatment of osteosarcoma, a cancer with few treatment improvements in decades.

Pathos AI enters collaboration with Bristol Myers Squibb

Pathos AI has entered into a collaboration with Bristol Myers Squibb.

Corxel to go public via SPAC merger with $300M financing

Obesity drugmaker Corxel Pharmaceuticals will go public through a SPAC merger backed by a $300 million financing, with two GLP-1 and amylin-targeting medicines in hand; the merger is expected to close in the first half of 2027, when Corxel plans to begin a Phase 3 trial of its oral GLP-1.